Introduction
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide [1] . While pharmacotherapy has not yet consistently demonstrated improved survival [2] , long-term oxygen therapy (LTOT) is capable of reducing mortality in advanced, hypoxemic COPD [3] . Noninvasive positive-pressure ventilation (NPPV) is established in the management of acute hypercapnic respiratory failure after severe exacerbation [4] , whereas the evidence in support of domiciliary, long-term NPPV in chronic hypercapnic COPD is equivocal. The review aims to integrate current clinical and pathophysiological concepts, indications for and the utility of noninvasive home mechanical ventilation (HMV), highlighting its impact on long-term outcome.
Indications
COPD with chronic hypercapnic respiratory failure (CHRF) has grown to be one of the major indications for HMV in Europe, as demonstrated by a survey of 21 526 patients from 329 centers [5] . This might imply a high conviction among clinicians regarding the clinical benefit from HMV in COPD, including the view that withholding this therapy could be life-threatening; however, clear-cut evidence that supports this view is still scarce. The survey did not provide details of the criteria of HMV, but significant differences between institutions and countries with regard to these and the willingness to prescribe HMV can be assumed.
According to the definition of CHRF [6] , elevated daytime arterial carbon dioxide tension (PaCO 2 ) is considered as a key indicator of alveolar hypoventilation and constitutes a major criterion for the decision to undertake HMV. Its use in COPD is often based on recommendations of an International Consensus Conference [7] . According to this, HMV should be considered after optimization of therapy including maximal bronchodilation and LTOT if typical symptoms are present and PaCO 2 levels are 55 mmHg or above, or if levels are lower (50-54 mmHg) but nocturnal oxygen desaturation of 88% or below occurs for 5 min or more consecutively despite continuous administration of 2 l/min or more of oxygen. This statement was derived from data demonstrating clinical effects from HMV on blood gases and sleep quality or quality of life in patients presenting with pronounced nocturnal hypoventilation and/or hypercapnia [8] . Conversely, in those randomized controlled trials which did not observe benefits, patients showed a lower degree of hypercapnia [9, 10] . In line with this, the Global Initiative on Obstructive Lung Disease (GOLD) proposed long-term HMV particularly in patients with marked daytime hypercapnia [11] .
A further indication for HMV is thought to be given at a lower degree of hypercapnia (PaCO 2 50-54 mmHg) if two or more episodes of hypercapnic respiratory decompensation occur per year [7] . This basically relied on reported benefits of HMV in COPD, diffuse bronchiectasis and cystic fibrosis, as reflected in a lower number of hospitalizations in the year after HMV compared to preceding years [12] [13] [14] [15] , suggesting a role for HMV beyond the reversal of chronic hypercapnia.
The critical limits of hypercapnia are not tightly defined or verified in prospective randomized controlled trials. Even more intriguing, some authors argue that the development of chronic hypercapnia might represent a natural wisdom preventing respiratory muscle fatigue [6] . This view obviously interferes with the rationale underlying HMV [16] . In fact, large observational studies performed prior to the widespread application of HMV found similar [17] or even lower [18] mortality in moderately hypercapnic compared to normocapnic patients. The prognostic value of chronic hypercapnia is thus not clear and base excess might constitute a more reliable parameter, reflecting the long-term metabolic response [19 ] . Nonetheless, extreme hypercapnia [18] or persistent hypercapnia following an acute exacerbation [20] seem to predict a poor long-term outcome.
Although PaCO 2 remains a hallmark of CHRF and its reduction a goal of HMV, none of the currently available recommendations defines a more detailed profile of patients eligible for HMV. This seems surprising in a systemic, multidimensional disease such as COPD. Particularly in most severe COPD, the risk of death or severe exacerbations [21, 22] does not appear to be adequately described by (chronic) hypercapnia alone. Probably more important long-term determinants are the reductions in functional reserves including airway obstruction [18, 23] , lung hyperinflation [24, 25] , nutritional deficits [23] and anemia [26] .
These risk factors, and their combination, imply a high susceptibility for exacerbations and instability, associated with a high risk of uncompensated respiratory failure and death [27] . Noninvasive HMV can reduce the work of breathing and evoke beneficial changes in the ventilatory pattern [28 ] , thus probably bolstering functional reserves and counteracting life-threatening events, including those originating during an exacerbation. Following this argument, it seems adequate to base the decision for HMV on an individual picture covering a broad range of risk factors. Such multidimensional approaches are already customary in decisions about lung volume reduction surgery or lung transplantation [11] .
In accordance with this, a recent controlled, although not randomized, study provided further evidence that patients showing a profile of known risk factors especially benefit from HMV [29 ] , which has to be corroborated in randomized controlled trials. Patients who experience a severe acute exacerbation requiring the use of NPPV in the hospital show a high risk for subsequent lifethreatening events [30] and the continuation of ventilatory support at home might help to stabilize their clinical state [31] . Correspondingly, a lower frequency of hospital admissions [12, 32, 33] and lower healthcare costs after initiation of HMV [33] have been reported. Moreover, in a recent observational study, maintenance HMV after a prolonged period of weaning implied improved long-term survival, compared to patients discharged without NIV, independent of the patient's age and duration of hospital stay [34 ] . As these data were also derived from a retrospective analysis, they need to be confirmed. At least they suggest an indication for HMV after difficult weaning, although possibly only in selected groups of patients and a certain time window. See Table 1 . Utility A large number of investigations have elucidated the long-term utility of ventilatory support in COPD, using a wide range of clinical outcome measures. Not surprisingly, in this multifaceted disease some issues remain controversial, but a recent review of 466 patients from six randomized and nine nonrandomized controlled trials argued that HMV could well have an adjunctive role in the management of COPD [28 ] , through improvement of health-related outcomes or respiratory function. Again this conclusion, although cautious and not covering patient eligibility, pointed towards a role for HMV beyond the relief of chronic hypercapnia, in contrast to a previous meta-analysis of four randomized controlled trials with mainly negative findings [35] .
Defining the role of HMV precisely is, however, difficult in view of the fact that the contributions of the mechanisms underlying noninvasive HMV are not clear [36] . The hypothesis that the resting of respiratory muscles allows them to restore their capacity is now being questioned as the leading factor in COPD [37] [38] [39] 40 ]. Although the activity of the diaphragm can be reduced by ventilatory support [41] [42] [43] , this does not appear to translate into an increase of inspiratory muscle strength, according to most of the controlled studies [28 ] . Other effects such as restoration of chemosensitivity, with subsequent improvements in PaCO 2 and alveolar hypoventilation, have been suggested as being more important [36, 44] . Thus, the amelioration of blood gases, particularly hypercapnia, during noninvasive ventilation and spontaneous breathing is now considered as a major target of long-term HMV and has been defined as a therapeutic goal in a current multicenter trial [45] . Not surprisingly, early randomized controlled studies in which this goal was not reached, mainly due to insufficient ventilation pressures or patient noncompliance, also showed no clinical effect [9, 10, 46] . Conversely, the improvement of daytime blood gases by HMV was accompanied by benefits regarding sleep quality and quality of life in a randomized controlled trial [8], similarly to noncontrolled trials [47, 48] .
Valuable insight into the potential of HMV has been gained from short-term controlled or cross-over trials. By applying NPPV during close supervision, ascertaining effective ventilation [38, 39, 42, 49, 50] , it was demonstrated to be capable of raising tidal volume or minute ventilation [38, 39, 42, 49, 50] , and of reducing respiratory frequency and effective respiratory impedance [38, 39] . These benefits occurred during both ventilatory support and subsequent spontaneous breathing [38, 39, 49] , and were correlated with the reduction of PaCO 2 levels [38, 49] . Ameliorations of the ventilatory pattern could not only underlie the sustained reduction of PaCO 2 level, but also the positive effects on respiratory muscle performance [51] and lung hyperinflation [38, 52] (Fig. 1 ), but these results need to be proven in long-term prospective controlled trials. In view of the pathophysiology of dyspnea [53] , it seems plausible that these functional improvements correspond to the reduction of dyspnea sensation -a consistent result of randomized controlled clinical trials [32, 39, 43, 54] as exemplified by the correlation between the physiological improvements and the Transition Dyspnea Index (TDI) [39] . The observed effects on breathing pattern and/or respiratory mechanics also imply a greater ventilatory reserve which could be advantageous during both physical exercise and exacerbations [28 ] (Fig. 1) .
As yet, however, exercise capacity as quantified by 6-min walk distance did not show changes after initiation of NPPV in most studies addressing this issue [8,10,46, 54,55]; it was found to be improved in only two short-term randomized controlled trials [39, 43] . Dynamic hyperinflation during exercise probably poses a mechanical limiting factor not amenable to nocturnal HMV [56] . Irrespective of this it seems a promising observation that high-intensity NPPV administered during walking can result in improved oxygenation, decreased dyspnea and increased walking distance [57 ] .
Of utmost importance for achieving these effects are sufficient levels of inspiratory pressure, including a low positive end-expiratory pressure, to assure effective ventilation. While the controlled studies with unfavorable outcome predominantly used low inspiratory pressures [9,10, 32,46,54], a 3-month randomized cross-over trial using levels of 18/2 mbar [8] demonstrated salutary effects on daytime blood gases. It might be reassuring in this respect that in clinical short-and long-term investigations [38, 42, 52 ] the observed changes in ventilatory pattern and PaCO 2 were related to inspiratory pressure levels.
In recent noncontrolled studies the improvement in PaCO 2 consistently occurred at inspiratory pressures up to 28 mbar which were still tolerated by the patients [52, 58] . It has also been demonstrated that, despite the leakage at higher pressure, the increase in pressure still caused a gain in minute ventilation [59] .
Moreover, the potential of HMV can only be fully utilized when the mental attitude of the patient is adequate and compliance sufficient. Clinical practice indicates that this requires experience and familiarization with the technique on the patients' side, plus modern ventilator technique. This is underlined by the observation that particularly in the early years of HMV high rates of nonacceptance and a lack of beneficial effects were reported [9, 10, 46] .
In view of pathophysiological interactions it seems reasonable to consider those patients as potentially suited for HMV who show a high risk of hypercapnic failure or death (see Indications) or present the greatest functional deficits and/or symptoms. This approach might be crosschecked against conditions for which positive effects have been reported. Apart from pronounced chronic hypercapnia, the presence of marked clinical symptoms should encourage the initiation of noninvasive HMV. Indeed, dyspnea or sleep quality are improved by HMV according to noncontrolled [60, 61] and controlled trials [8, 32, 39, 43, 54] .
The nonnegligible costs associated with this sophisticated therapy call for regular assessment of therapeutic effectiveness including patient willingness to continue HMV [36] . Some data indicate a benefit from HMV even in the case of not being used every day or only for a limited period of time [38, 39] . Even short-term usage has positive effects [42, 49, 50] . Thus, it seems questionable to retract the ventilator only because it is not used daily, as it might be helpful in periods of deterioration, provided that the patient has learnt its application.
Outcome
Although the improvement of physiological indices is desirable, it has to be kept in mind that these effects should additionally translate into a substantial clinical benefit. Long-term survival and health-related quality of life (HRQL) are probably most important in this respect, as in other chronic diseases. The question for a long-term benefit is also inevitable in view of the considerable consumption of resources.
Some of the available reports covered an observation period of sufficient length to address long-term HRQL or survival, but most of them in a small number of patients [8, 12, 32, 47, 48, 54, 60] . Regarding HRQL, it seems encouraging that the majority of controlled [8, 54] and noncontrolled studies [47, 48] on the long-term effects of HMV reported positive findings irrespective of the choice of generic or disease-specific questionnaires. It seems important to note that improvements in HRQL also occurred in measures specifically designed for patients with ventilatory failure, such as the Maugeri Foundation Respiratory Failure Questionnaire (MRF-28) [54] and the Severe Respiratory Insufficiency (SRI) questionnaire [62] Noninvasive home ventilation Budweiser et al. 131 which was recently also validated specifically for COPD undergoing HMV [63] .
Contrary to the predominantly favorable findings regarding HRQL, the two randomized clinical trials on long-term mortality which comprised samples of acceptable size and observation periods of 1 and 2 years, respectively, found no difference in survival rate between patients with HMV compared to LTOT alone [32, 54] . Treatment efficiency and inspiratory pressure levels might, however, have been too low [64, 65] . Although changes in overall treatment associated with HMV should be taken into account, it should be noted that survival rates of patients treated with noninvasive efficient HMV were higher than those of historical controls [12, 48] . In a further observational study comprising the as yet largest population and longest observation period, patients with noninvasive HMV presented with better long-term survival compared to patients who were not successfully adapted to this therapy [29 ] (Fig. 2) . Of course, as the control group was not chosen at random, these data also show weaknesses. Nonetheless, a detailed analysis which took into account the (minor) differences at baseline between the study and control group unequivocally indicated a benefit from HMV. These results are encouraging and fit well into the picture of functional benefits.
In view of the potential of domiciliary noninvasive ventilation to reduce overall healthcare costs, at least in patients with recurrent exacerbations [33] , HMV should thus be further evaluated in randomized controlled trials and samples of adequate size. As suggested [29 ] , factors in favor of an improved long-term outcome are the selective inclusion of patients with severe COPD and high risk for exacerbation or death, sustained adaptation to HMV, high pressure levels, and familiarization with the technique. Naturally, HMV can only be part of a comprehensive management strategy in COPD and CHRF, comprising nutritional support, optimized pharmacological therapy and LTOT [19 ] . Even in the terminal stage of the disease noninvasive ventilation can alleviate symptoms [66 ] , without the undesirable sideeffect of prolonging the process of dying.
Conclusion
In patients with COPD and CHRF, studies that used high pressure levels and ensured adequate compliance have shown beneficial effects on physiological measures and health-related outcomes such as dyspnea and quality of life. Data on long-term survival are currently weak, but promising. From recent findings it seems inappropriate to base the decision to undertake HMV on PaCO 2 alone. In particular, patients with unstable disease, recurrent hypercapnic decompensations, life-threatening events or high risk for death should be considered for long-term HMV. These patients should be part of prospective controlled trials to define the role of noninvasive HMV in severe hypercapnic COPD more precisely.
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